Amyris is an integrated renewable products company providing sustainable alternatives to petroleum-sourced products and rare materials. The Company uses its industrial synthetic biology platform to convert plant sugars into a variety of hydrocarbon molecules, flexible building blocks which can be used in a wide range of products. Amyris is commercializing these products both as renewable ingredients in cosmetics, flavors, fragrances, polymers, lubricants and consumer products and also as renewable diesel and jet fuels.
Company Growth (employees)
Type
Public
HQ
Emeryville, US
Founded
2003
Size (employees)
440 (est)
Website
amyris.com
Amyris was founded in 2003 and is headquartered in Emeryville, US

Key People/Management at Amyris

Kathleen Valiasek

Kathleen Valiasek

Chief Financial Officer
Eduardo Alvarez

Eduardo Alvarez

Chief Operating Officer
Joel Cherry

Joel Cherry

President, Research & Development
Cynthia Bryant

Cynthia Bryant

Senior Vice President Corporate Development & Collaborations
Caroline Hadfield

Caroline Hadfield

Senior Vice President, Personal Care
Jim Iacoponi

Jim Iacoponi

Senior Vice President, Business Operations & Optimization
Charles Kraft

Charles Kraft

Senior Vice President, Global Manufacturing & Process Development
John Melo

John Melo

Director, President & Chief Executive Officer, Amyris
Nicole Kelsey

Nicole Kelsey

General Counsel and Secretary
Christine Ofori

Christine Ofori

Chief Human Resources Officer

Amyris Office Locations

Amyris has offices in Emeryville and Techno Park
Emeryville, US (HQ)
100 5885 Hollis St
Techno Park, BR
Rua John Dalton, 301 - Bloco B - Edificio 3
Show all (2)

Amyris Financials and Metrics

Amyris Financials

Amyris's revenue was reported to be $67.2 m in FY, 2016
USD

Revenue (Q3, 2017)

24.2 m

Gross profit (Q3, 2017)

6.6 m

Gross profit margin (Q3, 2017), %

27%

Net income (Q3, 2017)

(70.6 m)

EBIT (Q3, 2017)

(24.1 m)

Market capitalization (16-Feb-2018)

194.4 m

Cash (30-Sep-2017)

15.9 m

EV

287.7 m
Amyris's current market capitalization is $194.4 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

41.1 m43.3 m34.2 m67.2 m

Revenue growth, %

5%(21%)97%

Cost of goods sold

38.3 m33.2 m37.4 m56.7 m

Gross profit

2.9 m10.1 m(3.2 m)10.5 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

7 m6 m9.3 m16.3 m7.9 m7.8 m8.6 m8.8 m9.6 m26.5 m13 m25.7 m24.2 m

Cost of goods sold

8.3 m6.2 m7.5 m10.1 m6.6 m11 m8.5 m11.2 m7.9 m14.9 m12.8 m17.3 m17.6 m

Gross profit

(1.3 m)(195 k)1.8 m6.2 m1.2 m(3.1 m)136 k(2.4 m)1.7 m11.7 m212 k8.4 m6.6 m

Gross profit Margin, %

(19%)(3%)19%38%16%(40%)2%(27%)18%44%2%33%27%
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

6.9 m42 m12 m27.2 m

Accounts Receivable

62.8 k

Inventories

9.5 m6.5 m5.9 m6.2 m

Current Assets

36.9 m73.6 m35.7 m59.1 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

5.8 m47.8 m88.8 m67.2 m43.8 m10.9 m10.9 m7.8 m822 k582 k1.3 m5.1 m15.9 m

Accounts Receivable

24.9 m

Inventories

7.9 m11.1 m14.8 m16.7 m11.4 m11.1 m11.1 m7.6 m10 m7.9 m7.1 m5.7 m6.4 m

Current Assets

25.3 m73.8 m116.8 m102.9 m69.3 m36.1 m34.6 m27.7 m21.5 m21.1 m24.1 m41 m62.3 m
    USDFY, 2013FY, 2014FY, 2015FY, 2016

    Net Income

    (234.9 m)2.2 m(218.1 m)(97.3 m)

    Depreciation and Amortization

    16.6 m15 m12.9 m11.4 m

    Accounts Receivable

    (4.4 m)(1.2 m)4.9 m(9.3 m)

    Accounts Payable

    (2.6 m)(3.2 m)4.4 m6.4 m
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

    Net Income

    (24.2 m)16.4 m(35.5 m)(36.7 m)(52.3 m)(99.4 m)(176.1 m)(15.3 m)(28.9 m)(48.6 m)(37.4 m)

    Depreciation and Amortization

    6.8 m9.9 m2.9 m5.7 m8.6 m2.7 m

    Accounts Receivable

    6 m5.2 m(1.5 m)(183 k)(1.9 m)4.9 m

    Accounts Payable

    8.5 m5.8 m4.6 m3 m7.3 m(810 k)1.2 m4.3 m450 k
      USDY, 2017

      EV/EBIT

      -11.9 x

      EV/CFO

      -11.3 x

      Revenue/Employee

      55 k

      Debt/Equity

      -0.6 x

      Debt/Assets

      0.8 x

      Financial Leverage

      -0.7 x
      Show all financial metrics

      Amyris Market Value History

      Amyris's Web-traffic and Trends

      Amyris Online and Social Media Presence

      Amyris News and Updates

      Synthetic Biology 2017 Global Key Players –Amyris, Inc. (U.S.), DowDuPont (U.S.), GenScript USA Inc. (U.S.), Intrexon Corporation (U.S.), Integrated DNA Technologies (IDT) (U.S.) Market Analysis And Forecast To 2022

      Wiseguyreports.Com Adds “Synthetic Biology-Market Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2022” To Its Research Database. Posted via Industry Today. Follow us on Twitter @IndustryToday

      Amyris Company Life and Culture

      You may also be interested in